Evidence map›Paper›PMID 27025356›Full record

ArticleJournal of virological methods2016

Development and validation of an oligonucleotide ligation assay to detect lamivudine resistance in hepatitis B virus.

Ingrid A Beck, Rachel Payant, Nicole Ngo-Giang-Huong, Woottichai Khamduang, Laddawan Laomanit, Gonzague Jourdain, Lisa M Frenkel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virological methods, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ingrid A BeckSeattle Children's Research Institute, Seattle, WA, USA.
Rachel PayantSeattle Children's Research Institute, Seattle, WA, USA.
Nicole Ngo-Giang-HuongUnité Mixte Internationale 174, Institut de Recherche pour le Développement (IRD)-Programs for HIV Prevention and Treatment (PHPT), Chiang Mai, Thailand; Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand; Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA, USA.
Woottichai KhamduangUnité Mixte Internationale 174, Institut de Recherche pour le Développement (IRD)-Programs for HIV Prevention and Treatment (PHPT), Chiang Mai, Thailand; Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand.
Laddawan LaomanitUnité Mixte Internationale 174, Institut de Recherche pour le Développement (IRD)-Programs for HIV Prevention and Treatment (PHPT), Chiang Mai, Thailand.
Gonzague JourdainUnité Mixte Internationale 174, Institut de Recherche pour le Développement (IRD)-Programs for HIV Prevention and Treatment (PHPT), Chiang Mai, Thailand; Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand; Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA, USA.
Lisa M FrenkelSeattle Children's Research Institute, Seattle, WA, USA; University of Washington, Seattle, WA, USA. Electronic address: lfrenkel@u.washington.edu.

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI Kenneth Sherr · 1988 to 2026
$104.9M
LC - IMPAACT Leadership GroupUM1AI106716 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$47.2M
NEVIRAPINE+ZIDOVUDINE--PREVENT PERINATAL HIV IN THAILANDR01HD039615 · NICHD · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI LALLEMANT, MARC J · 2000 to 2002
$3.7M
Drug-resistance testing in Kenya to improve ART suppression of HIV replicationR01AI100037 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI FRENKEL, LISA M · 2012 to 2014
$3.1M
Reservoirs of drug-resistant HIV-1R01AI058723 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI FRENKEL, LISA M · 2005 to 2009
$2.0M
NIAID NIH HHS P30 AI027757NIAID NIH HHS R01 AI058723NIAID NIH HHS R01 AI100037NIAID NIH HHS UM1 AI106716NICHD NIH HHS R01 HD039615NICHD NIH HHS R01HD 39615
6 · The paper itself

Abstract

Treatment of chronic hepatitis B virus (HBV) infection with lamivudine-monotherapy rapidly selects mutant variants in a high proportion of individuals. Monitoring lamivudine resistance by consensus sequencing is costly and insensitive for detection of minority variants. An oligonucleotide ligation assay (OLA) for HBV lamivudine-resistance was developed and compared to consensus sequencing. Both assays detected drug resistance mutations in 35/64 (54.7%) specimens evaluated, and OLA detected minority mutants in an additional six (9.4%). OLA may offer a sensitive and inexpensive alternative to consensus sequencing for detection of HBV drug resistance in resource-limited settings.

Indexed as

Cloning, MolecularDrug Resistance, ViralMicrobial Sensitivity TestsAntiviral AgentsGenes, ViralGenotypeHepatitis BHepatitis B virusHumansLamivudineMutationOligonucleotidesAntiviral AgentsLamivudineOligonucleotidesHBV drug resistanceHBV treatmentLamivudine resistanceOligonucleotide ligation assay

Identifiers

PMID27025356
PMCPMC5074383

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.